Cystic fibrosis other diagnostic studies

Jump to navigation Jump to search

Cystic fibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cystic fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cystic fibrosis other diagnostic studies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cystic fibrosis other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cystic fibrosis other diagnostic studies

CDC on Cystic fibrosis other diagnostic studies

Cystic fibrosis other diagnostic studies in the news

Blogs on Cystic fibrosis other diagnostic studies

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Cystic fibrosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

Other diagnostic studies in patients with cystic fibrosis include sweat chloride test (measures the chloride content of the sweat) and nasal potential differences (performed by running different solutions through the nose) which used to detect changes in CFTR function. A sweat chloride value of more than 59 mmol/L is diagnostic for cystic fibrosis and less than 30 mmol/L is unlikely cystic fibrosis.

Other Diagnostic Studies

Other diagnostic studies in patients with cystic fibrosis include:[1][2][3][4]

Sweat chloride test:

  • Sweat chloride test is an indicator of CFTR function and measures the chloride content of the sweat in the patients with cystic fibrosis. This test is critical to distinguish cystic fibrosis from other causes of severe pulmonary and pancreatic insufficency.
  • Sweat chloride test should performed as soon as possible (even in 48 hours after birth) when positive screening results are reported.
  • Sweat chloride test results are considered as follow:
    • More than 59 mmol/L: diagnostic for cystic fibrosis
    • 30-59 mmol/L: needs more evaluation with CFTR genetic analysis
    • Less than 30 mmol/L: unlikely cystic fibrosis
 
 
 
 
 
 
 
 
Sweat chloride test
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
≥60 mmol/L
 
 
 
30-59 mmol/L
 
 
 
≤29 mmol/L
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CFTR genetic analysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 CF-causing CFTR mutation
 
No CFTR mutations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EF diagnosis
 
 
 
 
 
 
 
 
 
CF unlikely

Nasal Potential Difference (NPD):

  • In patients with cystic fibrosis NPD is performed by running different solutions through the nose.
  • Voltage measurements from these solutions are used to detect changes in CFTR function.

References

  1. Pettit RS, Fellner C (July 2014). "CFTR Modulators for the Treatment of Cystic Fibrosis". P T. 39 (7): 500–11. PMC 4103577. PMID 25083129.
  2. Shah U, Moatter T (2006). "Screening for cystic fibrosis: the importance of using the correct tools". J Ayub Med Coll Abbottabad. 18 (1): 7–10. PMID 16773960.
  3. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR (February 2017). "Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation". J. Pediatr. 181S: S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064. PMID 28129811.
  4. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR (February 2017). "Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation". J. Pediatr. 181S: S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064. PMID 28129811.


Template:WikiDoc Sources